Jodie L. Babitt

Jodie L. Babitt

Auto-generated profile, based on publicly available information

Jodie L. Babitt

Nephrology Division and Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2012 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
JBJodie L. Babitt
Jodie L. Babitt
HLHerbert Y. Lin
Herbert Y. Lin
Anemia is a common feature of CKD associated with poor outcomes. The current management of patients with anemia in CKD is controversial, with recent clinical trials demonstrating increased morbidity and mortality related to erythropoiesis stimulating agents. Here, we examine recent insights into the molecular mechanisms underlying anemia of CKD. These insights hold promise for the development of new diagnostic tests and therapies that directly target the pathophysiologic processes underlying this form of anemia.

1 March 2009 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BJBilly Andriopoulos Jr
Billy Andriopoulos Jr
ECElena Corradini
Elena Corradini
YXYin Xia
Yin Xia
SFSarah A Faasse
Sarah A Faasse
SCShanzhuo Chen
Shanzhuo Chen
JBJodie L Babitt
Jodie L Babitt

15 March 2017 in Hemodialysis International
Verified
Journal Article
Open access
PDF file
SDSom Dev
Som Dev
JBJodie L. Babitt
Jodie L. Babitt
Iron is an essential element for numerous fundamental biologic processes, but excess iron is toxic. Abnormalities in systemic iron balance are common in patients with chronic kidney disease and iron administration is a mainstay of anemia management in many patients. This review provides an overview of the essential role of iron in biology, the regulation of systemic and cellular iron homeostasis, how imbalances in iron homeostasis contribute to disease, and the implications for chronic kidney disease patients.

3 January 2019 in Blood
Verified
Journal Article
Open access
PDF file
CWChia-Yu Wang
Chia-Yu Wang
JBJodie L. Babitt
Jodie L. Babitt
The liver orchestrates systemic iron balance by producing and secreting hepcidin. Known as the iron hormone, hepcidin induces degradation of the iron exporter ferroportin to control iron entry into the bloodstream from dietary sources, iron recycling macrophages, and body stores. Under physiologic conditions, hepcidin production is reduced by iron deficiency and erythropoietic drive to increase the iron supply when needed to support red blood cell production and other essential functions. Conversely, hepcidin production is induced by iron loading and inflammation to prevent the toxicity of iron excess and limit its availability to pathogens. The inability to appropriately regulate hepcidin production in response to these physiologic cues underlies genetic disorders of iron overload and deficiency, including hereditary hemochromatosis and iron-refractory iron deficiency anemia. Moreover, excess hepcidin suppression in the setting of ineffective erythropoiesis contributes to iron-loading anemias such as β-thalassemia, whereas excess hepcidin induction contributes to iron-restricted erythropoiesis and anemia in chronic inflammatory diseases. These diseases have provided key insights into understanding the mechanisms by which the liver senses plasma and tissue iron levels, the iron demand of erythrocyte precursors, and the presence of potential pathogens and, importantly, how these various signals are integrated to appropriately regulate hepcidin production. This review will focus on recent insights into how the liver senses body iron levels and coordinates this with other signals to regulate hepcidin production and systemic iron homeostasis.

1 May 2016 in Current Opinion in Hematology
Verified
Journal Article
Closed access
CWChia-Yu Wang
Chia-Yu Wang
JBJodie L. Babitt
Jodie L. Babitt
Purpose of review Anemia is prevalent in patients with infections and other inflammatory conditions. Induction of the iron regulatory hormone hepcidin has been implicated in the pathogenesis of anemia of inflammation. This review outlines recent discoveries in understanding how hepcidin and its receptor ferroportin are regulated, how they contribute to anemia of inflammation, and how this knowledge may help guide new diagnostic and therapeutic strategies for this disease. Recent findings IL-6 is a primary driver for hepcidin induction in many models of anemia of inflammation, but the SMAD1/5/8 pathway also contributes, likely via Activin B and SMAD-STAT3 interactions at the hepcidin promoter. Hepcidin has an important functional role in many, but not all forms of anemia of inflammation, although hepcidin-independent mechanisms also contribute. In certain populations, hepcidin assays may help target therapy with iron or erythropoiesis-stimulating agents to patients who may benefit most. New therapies targeting the hepcidin–ferroportin axis have shown efficacy in preclinical and early clinical studies. Summary Recent studies confirm an important role for the hepcidin–ferroportin axis in the development of anemia of inflammation, but also highlight the diverse and complex pathogenesis of this disorder depending on the underlying disease. Hepcidin-based diagnostic and therapeutic strategies offer promise to improve anemia treatment, but more work is needed in this area.

1 June 2021 in Kidney International
Verified
Journal Article
Open access
JBJodie L. Babitt
Jodie L. Babitt
MEMichele F. Eisenga
Michele F. Eisenga
VHVolker H. Haase
Volker H. Haase
AKAbhijit V. Kshirsagar
Abhijit V. Kshirsagar
ALAdeera Levin
Adeera Levin
MWMyles Wolf
Myles Wolf
In chronic kidney disease, anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluation, and treatment of anemia in chronic kidney disease. Since then, new data have accrued from basic research, epidemiological studies, and randomized trials that warrant a re-examination of previous recommendations. Therefore, in 2019, KDIGO decided to convene 2 Controversies Conferences to review the latest evidence, explore new and ongoing controversies, assess change implications for the current KDIGO anemia guideline, and propose a research agenda. The first conference, described here, focused mainly on iron-related issues, including the contribution of disordered iron homeostasis to the anemia of chronic kidney disease, diagnostic challenges, available and emerging iron therapies, treatment targets, and patient outcomes. The second conference will discuss issues more specifically related to erythropoiesis-stimulating agents, including epoetins, and hypoxia-inducible factor-prolyl hydroxylase inhibitors. Here we provide a concise overview of the consensus points and controversies resulting from the first conference and prioritize key questions that need to be answered by future research.